In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

##STR00001##

The resin composition of the present disclosure contains a fluorene derivative represented by the following formula (1) and a polyamide-series resin:

##STR00001##

Wherein R.sup.1 represents a substituent, k denotes an integer of 0 to 8, R.sup.2a, R.sup.2b, R.sup.2c, and R.sup.2d each represent a hydrogen atom or a substituent, R.sup.3a and R.sup.3b each represent a hydrogen atom or a substituent, and X.sup.1a and X.sup.1b each represent a group defined in the following formula (X1):

##STR00002##

wherein R.sup.4 and R.sup.5 each represent a hydrogen atom or a hydrocarbon group; or R.sup.4 and R.sup.5 bend together to form a heterocyclic ring containing the nitrogen atom adjacent to R.sup.4 and R.sup.5.

The resin composition has an excellent fluidity.

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured:

##STR00001## or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

The present disclosure relates generally to derivatives of pyrrolobenzodiazepines and antibody-drug conjugates thereof and to methods of using these conjugates as therapeutics and/or diagnostics.

The present invention discloses tricyclic compounds of formula (I) or salt thereof and their process for synthesis. Further, the present invention relates to the use of these novel tricyclic compounds of formula (I) or salt thereof as insect repellents.

##STR00001##

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging. ##STR00001##

This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: ##STR00001## or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

The resin composition of the present disclosure contains a fluorene derivative represented by the following formula (1) and a polyamide-series resin: ##STR00001##
Wherein R.sup.1 represents a substituent, k denotes an integer of 0 to 8, R.sup.2a, R.sup.2b, R.sup.2c, and R.sup.2d each represent a hydrogen atom or a substituent, R.sup.3a and R.sup.3b each represent a hydrogen atom or a substituent, and X.sup.1a and X.sup.1b each represent a group defined in the following formula (X1): ##STR00002##
wherein R.sup.4 and R.sup.5 each represent a hydrogen atom or a hydrocarbon group; or R.sup.4 and R.sup.5 bend together to form a heterocyclic ring containing the nitrogen atom adjacent to R.sup.4 and R.sup.5. The resin composition has an excellent fluidity.

This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.